PROCTER GAMBLE HEALTH LTD Q3 RESULTS
![Apollo 24/7 GMV to go up to Rs 1,000 cr per quarter over next 18 months: Suneeta Reddy](https://img.etimg.com/thumb/msid-112517541,width-100,height-75,resizemode-4/markets/expert-view/apollo-24/7-gmv-to-go-up-to-rs-1000-cr-per-quarter-over-next-18-months-suneeta-reddy.jpg)
Apollo 24/7 GMV to go up to Rs 1,000 cr per quarter over next 18 months: Suneeta Reddy
Apollo Hospitals' Suneeta Reddy forecasted a 5% price impact for next quarter, citing the recent muted performance from elections and a heatwave. Regional occupancy and margins varied, with Nashik serving as a referral center. Apollo 24/7 aims for Rs 1,000 crore quarterly in six quarters. AHLL is on an improving revenue trajectory despite new centers impacting margins.
![Metropolis Q1 results: Net profit rises 31% to Rs 38 crore](https://img.etimg.com/thumb/msid-112430513,width-100,height-75,resizemode-4/markets/stocks/earnings/metropolis-q1-results-net-profit-rises-31-to-rs-38-crore.jpg)
Metropolis Q1 results: Net profit rises 31% to Rs 38 crore
The earnings for interest, tax, depreciation and ammortisation (EBITDA) before CSR and ESOP rose 20.2% YoY to Rs 80.5 crore in Q1. The EBITDA margin in Q1FY25 was 25%.
![Alembic Pharma Q1 Results: Net profit rises 12% YoY to Rs 135 crore](https://img.etimg.com/thumb/msid-112381246,width-100,height-75,resizemode-4/markets/stocks/earnings/alembic-pharma-q1-results-net-profit-rises-12-yoy-to-rs-135-crore.jpg)
Alembic Pharma Q1 Results: Net profit rises 12% YoY to Rs 135 crore
Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 14% YoY to Rs 239 crore, while the EBITDA margins contracted 540 basis points on y-o-y basis to 15.3%
![PB Fintech Q1 Results: Policybazaar parent posts cons PAT of Rs 60 crore versus YoY loss; revenue jumps 52%](https://img.etimg.com/thumb/msid-112322545,width-100,height-75,resizemode-4/markets/stocks/earnings/pb-fintech-q1-results-policybazaar-parent-posts-cons-pat-of-rs-60-crore-versus-yoy-loss-revenue-jumps-52.jpg)
PB Fintech Q1 Results: Policybazaar parent posts cons PAT of Rs 60 crore versus YoY loss; revenue jumps 52%
During the April-June quarter, the company witnessed significant 62% year-over-year increase in total insurance premium, reaching Rs 4,871 crore. The new core online insurance premium surged by 66%, while new health and life insurance premiums experienced an even more substantial 78% growth. Additionally, the company disbursed Rs 3,100 crore in credit and issued 1.3 lakh credit cards during the same period.
![Airtel beats street view, Q1 net surges 158%](https://img.etimg.com/thumb/msid-112298328,width-100,height-75,resizemode-4/industry/telecom/telecom-news/airtel-beats-street-view-q1-net-surges-158.jpg)
Airtel beats street view, Q1 net surges 158%
Bharti Airtel reported a significant increase in its consolidated net profit for Q1 FY25, rising more than 150% year-over-year and doubling sequentially, driven by exceptional gains, improved average revenue per user (ARPU), and reduced finance costs. The telecom giant posted a net profit of ₹4,159.9 crore, exceeding analyst estimates.
- Go To Page 1
Bharti Airtel Q1 Results: Consolidated net profit doubled QoQ to Rs 4,159.9 crore
Bharti Airtel’s consolidated net profit rose 100.81% sequentially and 158% on-year to Rs 4159.9 crore, helped by a one-time gain in addition to strong broadband user additions and an increase in average revenue per user (ARPU).
Bharti Airtel Q1 Preview: Revenue may grow by 3% YoY to Rs 38,488 crore, outlook positive
Bharti Airtel is expected to report a revenue of Rs 38,488 crore for Q1 FY24, marking a 2.6% YoY increase. Net profit estimates range from Rs 2,068 crore to Rs 3,922 crore. Axis Securities has the highest revenue estimate at Rs 38,996 crore, and Prabhudas Lilladher forecasts a decline in adjusted PAT.
Mankind Pharma Q1 Results: Net profit jumps 10% to Rs 543 crore
The drug maker reported net profit of Rs 494 crore in the corresponding period of previous year.Revenue from operations rose 12.2% YoY to Rs 2,893 crore in Q1FY25. On a quarter-on-quarter (QoQ) basis revenue and net profit increased 18.5% and 14%, respectively.
Dabur Q1 Preview: Domestic volumes to drive revenue growth by 6% YoY; margins to expand
Dabur India’s revenue for Q1 2024 likely witnessed a 6% year-on-year growth, driven by rural market improvement and international business. Domestic volumes reportedly grew by 5-6%, with gross margins expected to improve by up to 200 bps YoY. Higher ad-spends were seen moderating EBITDA margins slightly.
Tata Consumer shares drop over 2% as Q1 results fail to impress. Should you invest?
Tata Consumer Products reported an 8% drop in profit after tax for the first quarter ended June 2024, falling to Rs 290 crore, below estimates. Shares fell 2.3%. Revenue from operations increased 16% year-on-year to Rs 4,352 crore. The drop in profit was attributed to higher exceptional items and lower returns from joint ventures and associates.
Cipla Q1 Results: Cons PAT rises 18% YoY to Rs 1,178 crore, beats estimates
Cipla Q1 Results: The profit beat the ET Now Poll estimates of Rs 1,071 crore. Revenue from operations in the reporting period increased 6% year-on-year to Rs 6,694 crore. EBITDA saw a 14% year-on-year increase, reaching Rs 1,716 crore. This growth was primarily driven by the One India business' branded prescription division, which experienced a 10% growth. This growth was particularly strong in focused chronic therapies like respiratory, cardiac, and urology, outpacing the market. The overall chronic mix in the portfolio also improved by 106 basis points year-on-year, reaching 61.5%.
Go Digit shares rally 8% after PAT jumps 74% in June quarter
Shares of Go Digit General Insurance rallied 8% on Friday to a day's high of Rs 362.25 on the BSE after the company reported a 74% increase in net profit for the quarter ended June 30, 2024, reaching Rs 101 crore, up from Rs 58 crore in the same period last year.
Go Digit Q1 results: PAT jumps 74% YoY to Rs 101 crore, AUM rises by 33%
The assets under management in the April-June 2024 quarter stood at Rs 17,773 crore up from Rs 13,337 crore in Q1FY24. It was a 33% year-on-year jump. On a sequential basis, the AUM grew by 12.7% compared to Rs 15,764 crore as at March 31, 2024.
L&T shares rise 2% after 12% YoY jump in PAT. Should you buy, sell or hold?
Larsen and Toubro (L&T)’s shares rose by 2% after it reported a consolidated net profit of Rs 2,786 crore for Q1 FY25. Revenue from operations saw a 15% YoY increase, driven by robust execution in projects and manufacturing. Orders grew by 8%, with strong momentum in the Middle East, per analysts insights.
Tech Mahindra Q1 Results Preview: Revenue may fall 2% YoY on seasonal impact; deal wins to be muted
According to an average estimate from four brokerages, revenue for the reporting period is expected to decline by 1.6% year-on-year. However, sequential revenue growth is projected to be between 0.3% and 0.9%. Meanwhile, the reported net profit for the April-June 2024 period is anticipated to increase by 24% year-on-year, based on the same average estimate from the brokerages.
L&T Q1 Results: Cons PAT jumps 12% YoY to Rs 2,786 cr, revenue rises 15%
L&T Q1 Results: Revenue from operations grew 15% YoY to Rs 55,120 crore, driven by strong performance in the projects and manufacturing (P&M) portfolio, supported by a substantial order book. In the first quarter, the company secured orders worth Rs 70,936 crore at the group level, showing an 8% year-on-year increase, thanks to robust ordering activity in the Middle East.
Budget 2024: ITC, Tata Consumer, other FMCG shares climb up to 5% on govt's rural, employment push
The government has made a provision of Rs 2.66 lakh crore for rural development including rural infrastructure. Finance Minister Nirmala Sitharaman, in her 7th Union Budget speech, also made a provision of Rs 1.52 lakh crore for agriculture and allied sector
HUL Q1 Results Today: Revenue growth seen to be flat, PAT uptick marginal
Axis remains most conservative on the PAT figures, estimating a 1% decline to Rs 2,479 crore in the April-June quarter while Prabhudas most bullish with estimates of 2.5% uptick at Rs 2,562 crore. As for the company revenue in the said quarter, Prabhudas has the highest estimates while Axis has the lowest one. A flat to 2% YoY revenue uptick is seen in Q1.
ICICI Lombard Q1 PAT up at Rs 580 crore on motor, health insurance boost
General insurance, especially the motor and health segments, has seen rapid growth in the country in recent years with a rise in vehicle sales and improved awareness following the Covid-19 pandemic and resultant medical costs
Go Digit Q4 Results: PAT jumps 104% YoY to Rs 53 crore; gross written premium up 19%
The net profit stood at Rs 182 crore for the full financial year as against Rs 36 crore in FY23, recording a 405% jump. The gross written premium for the full financial year stood at 9,016 crore versus Rs 7,243 crore in FY23.
Apollo Hospitals Q4 Results: Net profit rises 76% YoY to Rs 254 crore
Revenue grew 15% YoY to Rs.4,944 crore in Q4FY24. The earnings before interest, tax, depreciation and ammortisation (EBITDA), EBITDA rose 31% YoY to Rs.640 crore in Q4FY24. The EBITDA margins expanded 161 basis points YoY to 12.95%.
P&G Hygiene appoints Mrinalini Srinivasan as new CFO
Procter & Gamble Hygiene and Health Care Ltd named Mrinalini Srinivasan as its new Chief Financial Officer (CFO) starting June 29, 2024. With 16 years of finance experience, Srinivasan has successfully led projects across various P&G businesses in Asia, Middle East, and Africa. She aims to drive growth and consumer satisfaction in her new role. She succeeds Prashant Bhatnagar.
Global Health Q4 Results: Net profit rises 25% to Rs 127 crore
For the year ended on March 31, 2024, the company said its net profit increased to Rs 478 crore as against Rs 326 crore in FY23.
Medanta Q4 Results: Net profit jumps 26% YoY to Rs 127.3 crore
Global Health (Medanta) reported 26% year-on-year (YoY) jump in net profit to Rs 127.3 crore in Q4FY24 due to increase in revenue growth from matured and new hospitals, along with higher patient volumes.
Will the wave of restructuring help? 7 MNC pharma stocks with upside potential of up to 14%
In the last three years, Novartis is the third MNC pharma company which has announced sale of a part of its business in India. Some of these restructuring are being done as part of the global readjustment being made at the parent companies level. The bigger question is whether after this restructuring will the MNC pharma stocks, which have been underperforming for quite some time, be able to make a comeback on the street or not. This answer to this question would depend on multiple factors. Right from the use of the sale proceeds to whether post restructuring focus would be on a 100 percent subsidiary or not. In both positive and negative cases, these stocks probably should be on watchlist as news flow around them increases in coming quarters. We take a look at 7 MNC pharma companies.
Narayana Health Q3 Results: Net profit jumps 22% YoY to Rs 188 crore
The average revenue per occupied bed (ARPOB) was Rs 1.41 crore in Q3FY 24 as against Rs 1.3 crore in Q3FY23. The average length of stay (ALOS) stood at 4.4 days in Q3. The outpatient volumes rose 4% YoY to 6.04 lakh, while inpatient volumes were the same at 57,000.
Load More